A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY OF SUNITINIB IN METASTATIC COLORECTAL CANCER PATIENTS RECEIVING IRINOTECAN, 5-FLUOROURACIL AND LEUCOVORIN (FOLFIRI) AS FIRST LINE TREATMENT
收藏NIAID Data Ecosystem2026-03-06 收录
官方服务：
资源简介：
Primary objectives: To demonstrate that the combination of FOLFIRI plus sunitinib is superior to FOLFIRI plus placebo in prolonging the progression-free survival (PFS) in the first-line treatment of patients with metastatic colorectal cancer. Primary endpoints: Progression-free survival (PFS)
创建时间：
2007-05-15
